Radiation plus immunotherapy for advanced soft tissue sarcoma
Part of Cancer clinical trials.
This trial tests a new combination of radiation therapy and an immunotherapy approach (called PraG) for people with advanced soft tissue sarcoma that can't be removed by surgery or has spread. The goal is to see if this treatment can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of soft tissue sarcoma that is advanced, has come back, or has spread to other parts of the body.
- It has been at least 4 weeks since your last cancer treatment (surgery, chemo, or radiation), and any side effects have mostly healed.
- You have at least one tumor that can be measured on scans.
- Your general health is fairly good — you can take care of yourself and are able to walk.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding immunotherapy drugs (anlotinib and penpulimab) to radiation before surgery can help treat soft tissue sarcoma—a type of cancer in muscles, fat, or connective tissue. The goal is to shrink the tumor and improve surgical outcomes.
This trial tests a newer way of giving radiation (spatially fractionated) compared to standard radiation for people with large soft tissue sarcomas. It aims to see if the new method works better.
This trial tests if giving a short course of radiation therapy combined with immunotherapy before surgery can improve outcomes for people with soft tissue sarcoma in the belly or pelvis. It is for patients whose tumors are hard to remove completely without this pre-treatment.
This trial combines cryoablation (a freezing technique to destroy tumors) with camrelizumab (an immunotherapy drug that helps your immune system fight cancer) for patients with advanced soft tissue sarcoma that hasn't responded to standard treatments. The goal is to see if this combination works better than current options.
This trial tests a combination of targeted therapy, chemotherapy, and radiation for advanced soft tissue sarcoma that has not responded to standard treatment. It aims to see if the combination can help patients live longer or shrink their tumors.
This study tests a personalized vaccine made from your tumor's unique mutations, combined with special immune cells grown from your blood, to treat advanced sarcoma (bone or soft tissue cancer) that did not respond to initial treatment. The goal is to help your immune system recognize and attack cancer cells.
Hear when a new Soft Tissue Sarcoma (STS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.